Answers are grounded in this paper and cite their sources.
Heat shock protein 70 (HSP70) is a stress-responsive molecular chaperone involved in cellular homeostasis and immune regulation during pregnancy. Its circulating concentration may be altered in pre-eclampsia, but the available evidence remains inconsistent. The aim of this study was to evaluate circulating HSP70 concentrations in women with early- and late-onset pre-eclampsia compared with normotensive pregnant controls. A systematic review and meta-analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Overall, seven studies comprising 745 participants (371 women with pre-eclampsia and 374 controls) were included. Four datasets contributed to the early-onset analysis and four to the late-onset analysis, with one study providing separate cohorts for both subgroups. The pooled estimate suggested higher HSP70 concentrations in early-onset pre-eclampsia; however, the association was not statistically significant (SMD: 1.45; 95% CI: −0.58 to 3.47; p = 0.162). The late-onset analysis also demonstrated a non-significant pooled effect (SMD: 0.37; 95% CI: −1.75 to 2.49; p = 0.730). Considerable heterogeneity was observed in both analyses (I2 = 97.1% and 97.9%, respectively). Although most study-specific estimates suggested elevated circulating HSP70 concentrations in pre-eclampsia, particularly in early-onset disease, neither pooled analysis reached statistical significance. The current evidence does not demonstrate a consistent association between maternal circulating HSP70 and pre-eclampsia. Prospective studies using standardized onset definitions, sampling schedules, and laboratory methods are needed before HSP70 can be considered a biomarker.
No takes yet. Share an insight, caveat, or question.
Samara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: